AstraZeneca Canada v. Mylan Pharmaceuticals
In a first-of-its-kind ruling, the Federal Court of Can-ada decided on Feb. 7 in favor of Mylan Pharmaceuticals ULC’s argument that the patent for a combination drug to treat arthritis pain marketed by AstraZeneca Canada Inc. should be invalid based on the theory of obviousness. Mylan’s win means that generic (and presumably cheaper) forms of the drug will soon be available to Canadian consumers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
